Spironolactone in Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 250 participants.
Also called NCT02673463
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 250 participants
- Sponsor
- Registry
-
NCT02673463
-
- Other papers using this trial's data
- Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT02673463. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Spironolactone in Atrial Fibrillation
- Acronym
- IMPRESS-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Birmingham
Record details
- Record id
cardio:ct-nct02673463- Content hash
57dc43a2911fa982481a3143e3d61f46727fc2eefdb2ca0e89cc31dc0a3ccfe8